Xue Ming Qian
Directeur Général chez TRANSCENTA HOLDING LIMITED
Fortune : 7 M $ au 30/04/2024
Profil
Xue Ming Qian is the Chairman & Chief Executive Officer of Suzhou Chuangsheng Pharmaceutical Group Co., Ltd.
since 2012.
He is also the Chief Executive Officer & Executive Director of Transcenta Holding Ltd.
since 2010.
Dr. Qian is currently a Director at HJB (Hangzhou) Co. Ltd.
and a Member of the American Society of Clinical Oncology, Inc., the American Association for Cancer Research, the European Society for Medical Oncology, and the International Association for the Study of Lung Cancer.
Dr. Qian previously worked as a Principal Scientist at Amgen, Inc. from 1997 to 2010.
He was also a Senior Vice President, Head-Research & Development at Beijing Shenogen Pharma Group Ltd.
from 2010 to 2012.
Dr. Qian received his undergraduate degree from Fudan University in 1990, his graduate degree from Columbia University Vagelos College of Physicians & Surgeons in 1992, and his doctorate degree from Albany Medical College in 1998.
Dr. Qian is the founder of Suzhou Chuangsheng Pharmaceutical Group Co., Ltd.
(founded in 2012) and Transcenta Holding Ltd.
(founded in 2010).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/05/2024 | 28 240 788 ( 6,47% ) | 7 M $ | 30/04/2024 |
Postes actifs de Xue Ming Qian
| Sociétés | Poste | Début |
|---|---|---|
| TRANSCENTA HOLDING LIMITED | Directeur Général | 01/08/2010 |
Suzhou Chuangsheng Pharmaceutical Group Co., Ltd.
 Suzhou Chuangsheng Pharmaceutical Group Co., Ltd. BiotechnologyHealth Technology MabSpace Biosciences (Suzhou) Co., Ltd. engages in the development of therapeutic antibodies for cancer and fibrotic diseases. Its products include humanized programmed death-ligand 1, humanized vascular endothelial growth factor receptors 2, humanized OX40, and humanized colony stimulating factor 1 receptor antibodies. It also offers programmed death-ligand 1 antibodies for Immunohistochemistry detection and soluble programmed death ligand 1 measurement. The company was founded by Xue Ming Qian on October 18, 2012 and is headquartered in Suzhou, China. | Directeur Général | 18/10/2012 |
| HJB (Hangzhou) Co. Ltd. | Directeur/Membre du Conseil | - |
American Association for Cancer Research
 American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | - |
American Society of Clinical Oncology, Inc.
 American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Corporate Officer/Principal | - |
European Society for Medical Oncology
 European Society for Medical Oncology Medical/Nursing ServicesHealth Services The European Society for Medical Oncology (ESMO) is a leading medical oncology society that provides a professional network for its members and works with national societies across Europe. The non-profit company is based in Lugano, Switzerland. ESMO's position on a wide range of legislative and non-legislative policy files on both EU and levels is available to learn about. Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team. ESMO's Young Oncologists Corner is dedicated to providing educational and networking opportunities for medical oncologists under 40. | Corporate Officer/Principal | - |
| International Association for the Study of Lung Cancer | Corporate Officer/Principal | - |
Anciens postes connus de Xue Ming Qian
| Sociétés | Poste | Fin |
|---|---|---|
Beijing Shenogen Pharma Group Ltd.
 Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | Directeur Technique/Scientifique/R&D | 01/09/2012 |
| AMGEN INC. | Directeur Technique/Scientifique/R&D | 01/06/2010 |
| ░░░ ░░░░░░░░░░░░░ ░░░░░░░ ░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Xue Ming Qian
| Fudan University | Undergraduate Degree |
| Columbia University Vagelos College of Physicians & Surgeons | Graduate Degree |
| Albany Medical College | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| TRANSCENTA HOLDING LIMITED | Health Technology |
| AMGEN INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Suzhou Chuangsheng Pharmaceutical Group Co., Ltd.
Suzhou Chuangsheng Pharmaceutical Group Co., Ltd. BiotechnologyHealth Technology MabSpace Biosciences (Suzhou) Co., Ltd. engages in the development of therapeutic antibodies for cancer and fibrotic diseases. Its products include humanized programmed death-ligand 1, humanized vascular endothelial growth factor receptors 2, humanized OX40, and humanized colony stimulating factor 1 receptor antibodies. It also offers programmed death-ligand 1 antibodies for Immunohistochemistry detection and soluble programmed death ligand 1 measurement. The company was founded by Xue Ming Qian on October 18, 2012 and is headquartered in Suzhou, China. | Health Technology |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | Health Technology |
| HJB (Hangzhou) Co. Ltd. | |
American Association for Cancer Research
American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA. | Commercial Services |
American Society of Clinical Oncology, Inc.
American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Health Services |
European Society for Medical Oncology
European Society for Medical Oncology Medical/Nursing ServicesHealth Services The European Society for Medical Oncology (ESMO) is a leading medical oncology society that provides a professional network for its members and works with national societies across Europe. The non-profit company is based in Lugano, Switzerland. ESMO's position on a wide range of legislative and non-legislative policy files on both EU and levels is available to learn about. Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team. ESMO's Young Oncologists Corner is dedicated to providing educational and networking opportunities for medical oncologists under 40. | Health Services |
| International Association for the Study of Lung Cancer | |
| The International Society of Nephrology | Commercial Services |
